|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
EP3443979B2
(en)
|
2011-03-11 |
2026-05-20 |
Assistance Publique - Hôpitaux De Paris |
IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
|
|
US9669071B2
(en)
|
2011-03-11 |
2017-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for stimulating T lymphocytes with IL-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9481866B2
(en)
*
|
2011-12-16 |
2016-11-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T cell populations enriched for stable regulatory T-cells
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
US9580486B2
(en)
*
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
PT3102595T
(pt)
*
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
EP3129493B1
(en)
|
2014-04-09 |
2021-07-07 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
|
JP6592505B2
(ja)
*
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
KR102493543B1
(ko)
*
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア， インコーポレイテッド |
自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
|
|
AU2016246152A1
(en)
*
|
2015-04-10 |
2017-11-02 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
*
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
SG11201808552XA
(en)
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
TWI821192B
(zh)
|
2017-07-11 |
2023-11-11 |
美商新索思股份有限公司 |
非天然核苷酸之導入及其方法
|
|
IL321812A
(en)
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
EP3678677A4
(en)
*
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
ANTIGEN-PRESENTING POLYPEPTIDES AND METHOD FOR THEIR USE
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
CN111868079B
(zh)
*
|
2017-12-27 |
2025-06-17 |
协和麒麟株式会社 |
Il-2变体
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
US12565525B2
(en)
|
2018-03-28 |
2026-03-03 |
Ascendis Pharma Oncology Division A/S |
IL-2 conjugates
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
EP3836954B1
(en)
|
2018-08-13 |
2025-05-07 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
TW202031284A
(zh)
|
2018-11-08 |
2020-09-01 |
美商新索思股份有限公司 |
介白素10結合物及其用途
|
|
TW202034945A
(zh)
|
2018-12-21 |
2020-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種人白細胞介素２變體或其衍生物
|
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
CN119708241A
(zh)
|
2019-02-15 |
2025-03-28 |
因特格尔莫来库乐有限公司 |
密封蛋白6抗体及其用途
|
|
CN119350468A
(zh)
*
|
2019-03-29 |
2025-01-24 |
居里研究所 |
具有经修饰的生物活性的白介素-2变体
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
JP7778571B2
(ja)
*
|
2019-06-05 |
2025-12-02 |
アッシャー バイオセラピューティクス， インコーポレイテッド |
免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
|
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
CN114555634B
(zh)
|
2019-08-13 |
2025-01-10 |
美国安进公司 |
用于扩增调节性t细胞的白介素-2突变蛋白
|
|
AU2020329933A1
(en)
*
|
2019-08-15 |
2022-03-24 |
Cytimm Therapeutics, Inc. |
Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
|
|
CA3148135A1
(en)
|
2019-08-23 |
2021-03-04 |
Carolina E. CAFFARO |
Il-15 conjugates and uses thereof
|
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
TW202128961A
(zh)
|
2019-11-20 |
2021-08-01 |
美商安維塔生物科學股份有限公司 |
細胞激素融合蛋白及其醫藥組合物及治療應用
|
|
US20230036793A1
(en)
|
2019-12-12 |
2023-02-02 |
Iltoo Pharma |
Interleukin 2 chimeric constructs
|
|
PE20221506A1
(es)
|
2019-12-17 |
2022-10-04 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
KR20220140514A
(ko)
|
2020-01-10 |
2022-10-18 |
브라이트 피크 테라퓨틱스 아게 |
변형된 il-2 폴리펩타이드 및 그의 용도
|
|
AU2021205981A1
(en)
|
2020-01-11 |
2022-07-14 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
MX2022008770A
(es)
*
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Muteinas de la il2.
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
KR102986821B1
(ko)
|
2020-04-22 |
2026-07-06 |
머크 샤프 앤드 돔 엘엘씨 |
인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
|
|
EP4143329A4
(en)
|
2020-04-28 |
2024-10-16 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
|
IL296209A
(en)
|
2020-05-12 |
2022-11-01 |
Cue Biopharma Inc |
Multimeric t-cell modulatory polypeptides and methods of using them
|
|
CA3178074A1
(en)
|
2020-06-03 |
2021-12-09 |
Nina Gunnarsson |
Il-2 sequences and uses thereof
|
|
MX2023000734A
(es)
*
|
2020-07-14 |
2023-02-13 |
Pfizer |
Virus vaccinia recombinante.
|
|
AU2021335032A1
(en)
*
|
2020-08-28 |
2023-03-09 |
Ascendis Pharma Oncology Division A/S |
Glycosylated IL-2 proteins and uses thereof
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
US20240325495A1
(en)
|
2020-10-29 |
2024-10-03 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
CN112279906B
(zh)
*
|
2020-10-30 |
2022-09-20 |
浙江新码生物医药有限公司 |
人白细胞介素2-聚乙二醇偶联物及其制备方法与应用
|
|
US20230398183A1
(en)
|
2020-11-13 |
2023-12-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
|
|
CA3203977A1
(en)
*
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
CN113321722A
(zh)
*
|
2021-04-13 |
2021-08-31 |
苏州复融生物技术有限公司 |
白介素2突变体及其应用
|
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
|
KR20240034221A
(ko)
|
2021-07-09 |
2024-03-13 |
브라이트 피크 테라퓨틱스 아게 |
염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
KR20240036511A
(ko)
|
2021-07-30 |
2024-03-20 |
윈취안 바이오테크놀로지 (베이징) 씨오., 엘티디. |
인간 인터루킨-2 변이체 및 이의 용도
|
|
CN118414160A
(zh)
|
2021-10-06 |
2024-07-30 |
艾尔图制药公司 |
对发炎组织具有靶向特异性的白介素2嵌合构建体
|
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
AU2022477937A1
(en)
|
2022-09-12 |
2025-04-10 |
Assistance Publique - Hôpitaux De Paris |
Interleukin-2 for use in treating autism spectrum disorder
|
|
CN120282987A
(zh)
|
2022-11-30 |
2025-07-08 |
因特格尔莫来库乐有限公司 |
包括双特异性型式的针对紧密连接蛋白6的抗体
|
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
US20260028384A1
(en)
|
2024-04-17 |
2026-01-29 |
Visterra, Inc. |
Use of il-2 variant for treating kidney transplant rejection
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
EP4707295A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|
|
EP4707296A1
(en)
|
2024-09-05 |
2026-03-11 |
Egle Therapeutics |
Interleukin-2 variants with modified biological activity
|
|
WO2026154422A1
(en)
|
2025-01-17 |
2026-07-23 |
Otsuka Pharmaceutical Company, Ltd. |
Il-2-fc fusion protein for use in treating autoimmune diseases
|
|
WO2026159300A1
(en)
|
2025-01-24 |
2026-07-30 |
Iltoo Pharma |
M3c65 antibody and derivatives thereof for targeting inflammation
|